Investigational new drugs for the treatment of chronic renal failure : an overview of the literature
INTRODUCTION: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications.
AREAS COVERED: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website.
EXPERT OPINION: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 33(2024), 4 vom: 02. Apr., Seite 319-334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Terzo, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2024.2326624 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369197550 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369197550 | ||
| 003 | DE-627 | ||
| 005 | 20240408232516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2024.2326624 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369197550 | ||
| 035 | |a (NLM)38429874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Terzo, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigational new drugs for the treatment of chronic renal failure |b an overview of the literature |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a 'silent killer' for its sudden onset without symptoms in the early stages of the disease. The main goal of nephrologists is to slow the progression of kidney disease and treat the associated symptoms with a range of new medications | ||
| 520 | |a AREAS COVERED: The aim of this systematic review is to analyze the new investigational drugs for the treatment of chronic renal failure. Data were obtained from the available scientific literature and from the ClinicalTrials.gov website | ||
| 520 | |a EXPERT OPINION: Among the drugs currently being researched, SGLT2 inhibitors appear to be the most promising drugs for the treatment of CKD, has they have slower progression of CKD and protection of cardiorenal function. An important role in the future of CKD treatment is played by autologous cell-therapy, which appears to be a new frontier in the treatment of CKD. Other therapeutic strategies are currently being investigated and have been shown to slow the progression of CKD. However, further studies are needed to determine whether these approaches may offer benefits in slowing the progression of CKD in the near future | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a HIF inhibitors | |
| 650 | 4 | |a SGLT2i | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a diabetic kidney disease | |
| 650 | 4 | |a novel treatments | |
| 650 | 4 | |a renal failure | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 700 | 1 | |a Gembillo, Guido |e verfasserin |4 aut | |
| 700 | 1 | |a Cernaro, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Longhitano, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Calabrese, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Casuscelli, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Peritore, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Domenico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 33(2024), 4 vom: 02. Apr., Seite 319-334 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:319-334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2024.2326624 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2024 |e 4 |b 02 |c 04 |h 319-334 | ||